Forward Pharma A/S (FWP) Reaches $3.07 52-Week Low; Nanthealth (NH) Shorts Lowered By 8.57%

February 10, 2018 - By Michael Collier

Nanthealth Incorporated (NASDAQ:NH) had a decrease of 8.57% in short interest. NH’s SI was 3.29 million shares in February as released by FINRA. Its down 8.57% from 3.60 million shares previously. With 181,700 avg volume, 18 days are for Nanthealth Incorporated (NASDAQ:NH)’s short sellers to cover NH’s short positions. The SI to Nanthealth Incorporated’s float is 9.93%. The stock increased 1.36% or $0.04 during the last trading session, reaching $2.98. About 156,060 shares traded. NantHealth, Inc. (NASDAQ:NH) has 0.00% since February 10, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Forward Pharma A/S (NASDAQ:FWP) hit a new 52-week low and has $2.79 target or 9.00% below today’s $3.07 share price. The 8 months bearish chart indicates high risk for the $144.86 million company. The 1-year low was reported on Feb, 10 by Barchart.com. If the $2.79 price target is reached, the company will be worth $13.04 million less. The stock increased 1.99% or $0.06 during the last trading session, reaching $3.07. About 51,951 shares traded. Forward Pharma A/S (NASDAQ:FWP) has risen 4.69% since February 10, 2017 and is uptrending. It has underperformed by 12.01% the S&P500.

Among 5 analysts covering Nant Health (NASDAQ:NH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nant Health had 5 analyst reports since June 27, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Monday, June 27 by Jefferies. The stock of NantHealth, Inc. (NASDAQ:NH) earned “Outperform” rating by Cowen & Co on Monday, June 27. Canaccord Genuity initiated the stock with “Buy” rating in Monday, June 27 report. FBR Capital initiated the shares of NH in report on Monday, June 27 with “Outperform” rating. On Monday, June 27 the stock rating was initiated by First Analysis with “Overweight”.

NantHealth, Inc. operates as an evidence personalized healthcare company. The company has market cap of $318.73 million. The firm engages in converging science and technology through an integrated clinical platform to provide health information at the point of care for critical illnesses. It currently has negative earnings. It develops NantHealth solutions, an adaptive learning system, including molecular profiling solution, software, middleware, and hardware systems infrastructure that collects, indexes, analyzes, and interprets various molecular, clinical, operational, and financial data points derived from novel and traditional sources to enhance decision-making.

Among 3 analysts covering Forward Pharma (NASDAQ:FWP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Forward Pharma had 10 analyst reports since September 9, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Monday, April 3 by Jefferies. The firm has “Market Perform” rating given on Monday, April 3 by JMP Securities. The rating was maintained by Jefferies on Tuesday, September 26 with “Hold”. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. As per Monday, June 26, the company rating was maintained by Jefferies. Jefferies maintained the stock with “Hold” rating in Friday, October 27 report. The firm earned “Buy” rating on Wednesday, September 9 by Jefferies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Michael Collier

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: